Study Evaluating IMA-638 in Asthma

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupDouble-blindDiagnostic

Summary

The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.

Timeline

Start: 2006-02
Primary completion: —
Completion: 2007-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anrukinzumab	Monoclonal antibody	—	Subcutaneous

Study Evaluating IMA-638 in Asthma

Summary

Timeline

Drugs

Indications